Pfizer to buy Medivation for $14B

Posted online August 22, 2016 | 11:41 am

Pfizer Inc. penned a deal to purchase biotech company Medivation Inc. for $14 billion.

The $81.50 per share acquisition would give Pfizer access to Xtandi, a drug used to treat prostate cancer.

The deal is expected to close in the third or fourth quarter this year.

Read more from The Wall Street Journal.

Comments

No comments on this story |

Please log in to add your comment

Republic School District opens activities center

Editors' Pick

Fall 2026 Architects & Engineers Project Report

This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.

Most Read